journal article·2023-05-09

Effect of Cholesterol on Biomimetic Membrane Curvature and Coronavirus Fusion Peptide Encapsulation

Izabela Milogrodzka, Duy Tue Nguyen Pham, Gopal R. Sama, Hajar Samadian, Jiali Zhai, Liliana de Campo, Nigel M. Kirby, Timothy F. Scott, Mark M. Banaszak Holl, Leonie van ‘t Hag

ACS Nano· Volume 17· Issue 9
Publisher page

Abstract

Biomimetic cubic phases can be used for protein encapsulation in a variety of applications such as biosensors and drug delivery. Cubic phases with a high concentration of cholesterol and phospholipids were obtained herein. It is shown that the cubic phase structure can be maintained with a higher concentration of biomimetic membrane additives than has been reported previously. Opposing effects on the curvature of the membrane were observed upon the addition of phospholipids and cholesterol. Furthermore, the coronavirus fusion peptide significantly increased the negative curvature of the biomimetic membrane with cholesterol. We show that the viral fusion peptide can undergo structural changes leading to the formation of hydrophobic α-helices that insert into the lipid bilayer. This is of high importance, as a fusion peptide that induces increased negative curvature as shown by the formation of inverse hexagonal phases allows for greater contact area between two membranes, which is required for viral fusion to occur. The cytotoxicity assay showed that the toxicity toward HeLa cells was dramatically decreased when the cholesterol or peptide level in the nanoparticles increased. This suggests that the addition of cholesterol can improve the biocompatibility of the cubic phase nanoparticles, making them safer for use in biomedical applications. As the results, this work improves the potential for the biomedical end-use applications of the nonlamellar lipid nanoparticles and shows the need of systematic formulation studies due to the complex interplay of all components.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia

School of Science, STEM College, RMIT University, Melbourne, VIC 3000, Australia

Australian Centre for Neutron Scattering, Australian Nuclear Science and Technology Organisation, Kirrawee, NSW 2234, Australia

Australian Synchrotron, 800 Blackburn Road, Clayton, VIC 3168, Australia

Department of Materials Science and Engineering, Monash University, Clayton, VIC 3800, Australia

Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States

Funding

Horizon 2020 Framework Programme · Australian Institute of Nuclear Science and Engineering

References (92)

Show source-provided references
1. Cooper G. M. · 2014 · 89 · 399
2. 10.1038/4240810.1038/42408 ↗
3. 10.1016/j.chemphyslip.2015.05.00810.1016/j.chemphyslip.2015.05.008 ↗
4. 10.1016/j.colsurfb.2016.02.00310.1016/j.colsurfb.2016.02.003 ↗
5. 10.1517/1742524090288702910.1517/17425240902887029 ↗
6. 10.1517/17425247.3.2.17710.1517/17425247.3.2.177 ↗
7. 10.1517/17425247.3.6.73910.1517/17425247.3.6.739 ↗
8. 10.1002/bip.2098910.1002/bip.20989 ↗
9. 10.1016/S0006-3495(03)74726-210.1016/S0006-3495(03)74726-2 ↗
10. 10.1039/c3sm27743g10.1039/c3sm27743g ↗
11. 10.1021/cg401895410.1021/cg4018954 ↗
12. 10.1021/acs.langmuir.5b0325610.1021/acs.langmuir.5b03256 ↗
13. 10.1021/acsnano.8b0796110.1021/acsnano.8b07961 ↗
14. 10.1016/j.jcis.2012.10.01410.1016/j.jcis.2012.10.014 ↗
15. 10.1016/S1359-0294(00)00020-010.1016/S1359-0294(00)00020-0 ↗
16. 10.1038/4240810.1038/42408 ↗
17. 10.1146/annurev.cellbio.14.1.11110.1146/annurev.cellbio.14.1.111 ↗
18. 10.1038/nchembio.180010.1038/nchembio.1800 ↗
19. 10.1098/rsta.2015.012510.1098/rsta.2015.0125 ↗
20. 10.1021/acs.jpclett.6b0117310.1021/acs.jpclett.6b01173 ↗
21. 10.1016/j.ijpharm.2011.09.02210.1016/j.ijpharm.2011.09.022 ↗
22. 10.1021/ar100120v10.1021/ar100120v ↗
23. 10.1039/C6SM02487D10.1039/C6SM02487D ↗
24. 10.1021/acs.langmuir.6b0404510.1021/acs.langmuir.6b04045 ↗
25. 10.1039/C4NR05200E10.1039/C4NR05200E ↗
26. 10.1002/anie.20180406710.1002/anie.201804067 ↗
27. 10.1021/acsabm.8b0053910.1021/acsabm.8b00539 ↗
28. 10.1039/C6CS00663A10.1039/C6CS00663A ↗
29. 10.1016/j.antiviral.2020.10479210.1016/j.antiviral.2020.104792 ↗
30. 10.1038/ncomms1509210.1038/ncomms15092 ↗
31. 10.1128/JVI.78.13.6938-6945.200410.1128/JVI.78.13.6938-6945.2004 ↗
32. 10.1038/s41598-019-48541-210.1038/s41598-019-48541-2 ↗
33. 10.1016/j.virol.2017.12.01510.1016/j.virol.2017.12.015 ↗
34. 10.1523/JNEUROSCI.23-08-03262.200310.1523/JNEUROSCI.23-08-03262.2003 ↗
35. 10.1074/jbc.M50380520010.1074/jbc.M503805200 ↗
36. 10.1186/1756-6606-7-910.1186/1756-6606-7-9 ↗
37. 10.3390/ijms2202079810.3390/ijms22020798 ↗
38. 10.1007/s00232-004-0669-810.1007/s00232-004-0669-8 ↗
39. 10.1038/nrm241710.1038/nrm2417 ↗
40. Harald J. · Eur. J. Med. Res. · 2008 · 13 · 73
41. 10.1002/jss.40008040410.1002/jss.400080404 ↗
42. 10.1007/s12013-017-0792-710.1007/s12013-017-0792-7 ↗
43. Lüder W. · 1993 · 37 · 624
44. 10.1016/S0163-7827(01)00020-010.1016/S0163-7827(01)00020-0 ↗
45. 10.1016/S0006-3495(97)78067-610.1016/S0006-3495(97)78067-6 ↗
46. 10.1074/jbc.R00000520010.1074/jbc.R000005200 ↗
47. 10.1016/j.virol.2008.08.02610.1016/j.virol.2008.08.026 ↗
48. 10.1194/jlr.M700479-JLR20010.1194/jlr.M700479-JLR200 ↗
49. 10.1021/bi100891z10.1021/bi100891z ↗
50. 10.1038/nchembio.180010.1038/nchembio.1800 ↗
51. 10.1016/j.chemphyslip.2016.05.00310.1016/j.chemphyslip.2016.05.003 ↗
52. 10.1021/acs.langmuir.7b0271610.1021/acs.langmuir.7b02716 ↗
53. 10.1016/j.bbalip.2020.15884910.1016/j.bbalip.2020.158849 ↗
54. 10.1016/S0006-3495(02)75339-310.1016/S0006-3495(02)75339-3 ↗
55. 10.1016/S0006-3495(02)75339-310.1016/S0006-3495(02)75339-3 ↗
56. 10.1021/la800413510.1021/la8004135 ↗
57. 10.1016/0005-2736(87)90020-410.1016/0005-2736(87)90020-4 ↗
58. 10.1016/S0006-3495(99)77369-810.1016/S0006-3495(99)77369-8 ↗
59. 10.1016/S0006-3495(98)74056-110.1016/S0006-3495(98)74056-1 ↗
60. 10.1126/science.107435410.1126/science.1074354 ↗
61. 10.1016/S0142-9612(99)00126-X10.1016/S0142-9612(99)00126-X ↗
62. 10.1039/C4SM02343A10.1039/C4SM02343A ↗
63. 10.1039/C5SM00311C10.1039/C5SM00311C ↗
64. 10.1038/s41467-018-02996-510.1038/s41467-018-02996-5 ↗
65. 10.1021/acs.langmuir.9b0064710.1021/acs.langmuir.9b00647 ↗
66. 10.1039/C6CS00663A10.1039/C6CS00663A ↗
67. 10.1073/pnas.080995910610.1073/pnas.0809959106 ↗
68. 10.1016/S0005-2736(03)00169-X10.1016/S0005-2736(03)00169-X ↗
69. 10.1126/science.143980310.1126/science.1439803 ↗
70. 10.1021/bi00106a02010.1021/bi00106a020 ↗
71. 10.1016/0014-5793(95)00927-210.1016/0014-5793(95)00927-2 ↗
72. 10.1038/nprot.2006.20210.1038/nprot.2006.202 ↗
73. 10.3762/bjnano.11.1010.3762/bjnano.11.10 ↗
74. 10.1186/1471-2105-9-4010.1186/1471-2105-9-40 ↗
75. 10.1038/nchem.156810.1038/nchem.1568 ↗
76. 10.1038/nrd359110.1038/nrd3591 ↗
77. 10.1038/nchem.156810.1038/nchem.1568 ↗
78. 10.1107/S002188981302774X10.1107/S002188981302774X ↗
79. 10.1107/S205979831601717410.1107/S2059798316017174 ↗
80. 10.1021/ar300285u10.1021/ar300285u ↗
81. 10.1021/acs.langmuir.6b0105810.1021/acs.langmuir.6b01058 ↗
82. 10.1021/la970897m10.1021/la970897m ↗
83. 10.1080/10448632.2016.116398010.1080/10448632.2016.1163980 ↗
84. 10.1107/S160057671801800910.1107/S1600576718018009 ↗
85. 10.1016/j.nima.2014.07.02910.1016/j.nima.2014.07.029 ↗
86. 10.1002/pro.415310.1002/pro.4153 ↗
87. 10.1021/bi00504a00610.1021/bi00504a006 ↗
88. 10.1016/0003-2697(90)90396-Q10.1016/0003-2697(90)90396-Q ↗
89. 10.1107/S090904950800960610.1107/S0909049508009606 ↗
90. 10.1016/j.ab.2004.08.03510.1016/j.ab.2004.08.035 ↗
91. 10.1038/nprot.2010.510.1038/nprot.2010.5 ↗
92. 10.1002/0471250953.bi0508s5210.1002/0471250953.bi0508s52 ↗